An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Dezamizumab (Primary) ; Miridesap (Primary) ; Miridesap (Primary)
- Indications Amyloidosis
- Focus Diagnostic use; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 02 Apr 2018 Planned initiation date changed from 30 Mar 2018 to 5 Apr 2018.
- 15 Mar 2018 Planned initiation date changed from 3 Mar 2018 to 30 Mar 2018.
- 21 Feb 2018 Planned End Date changed from 11 Dec 2018 to 18 Dec 2018.